QQQ $ 430.17 $ -2.06 (-0.48 %)
DIA $ 380.88 $ -3.52 (-0.92 %)
SPY $ 507.81 $ -1.92 (-0.38 %)
TLT $ 87.78 $ -0.62 (-0.7 %)
GLD $ 215.92 $ 1.28 (0.6 %)
$ 0.298
-- x --
-- x --
-- - --
$ 0.24 - $ 0.39
5,242
na
34.19M
$ 0.72
nm
TBD
na
na ($ 15.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2023 09-30-2023 10-Q
2 08-14-2023 06-30-2023 10-Q
3 05-11-2023 03-31-2023 10-Q
4 03-28-2023 12-31-2022 10-K
5 11-10-2022 09-30-2022 10-Q
6 08-11-2022 06-30-2022 10-Q
7 05-12-2022 03-31-2022 10-Q
8 03-31-2022 12-31-2021 10-K
9 12-09-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 whats-going-on-with-lianbio-lian-stock

LianBio shares are trading higher by some 84% to $0.35 Friday afternoon on continued volatility. The company in late February a...

 lianbio-reports-voluntarily-delisting-from-nasdaq

LianBio expects to file a Form 25 with the SEC and Nasdaq relating to the voluntary delisting of its ADSs on or about March 11,...

 why-ipg-photonics-shares-are-trading-lower-by-around-11-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed four...

 ecolab-posts-strong-results-joins-masonite-international-impinj-and-other-big-stocks-moving-higher-on-tuesday

U.S. stocks were lower, with the Dow Jones index dipping more than 500 points on Tuesday.

 b-of-a-securities-downgrades-lianbio-to-underperform-lowers-price-target-to-3

B of A Securities analyst Geoff Meacham downgrades LianBio (NASDAQ:LIAN) from Buy to Underperform and lowers the price targe...

Core News & Articles

- SEC Filing

Core News & Articles

- SEC Filing

Core News & Articles

LianBio announced that the company has entered into an agreement with Janssen Pharmaceutica NV ("Janssen"), a Johnson &...

 jefferies-downgrades-lianbio-to-hold-lowers-price-target-to-4

Jefferies analyst Michael Yee downgrades LianBio (NASDAQ:LIAN) from Buy to Hold and lowers the price target from $7 to $4.

 lianbio-announces-departure-of-chief-financial-officer-yi-larson-effective-december-19-2023-board-of-directors-has-appointed-ehong-maggie-gu-current-vp-head-of-global-finance-as-interim-chief-financial-officer

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major ...

 lianbio-says-ceo-yizhe-wang-has-resigned-to-pursue-other-opportunities-adam-stone-named-as-interim-ceo

LianBio's Board of Directors will continue to represent the best interests of LianBio and its shareholders and evaluate str...

 lianbios-board-of-directors-unanimously-determines-not-to-pursue-unsolicited-proposal-from-concentra-biosciences

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major ...

 lianbio-q3-eps-022-beats-030-estimate

LianBio (NASDAQ:LIAN) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.30) by 26...

 lianbio-announces-topline-results-from-phase-3-libra-trial-of-tp-03-in-chinese-patients-with-demodex-blepharitis-the-co-primary-endpoints-of-the-libra-trial-were-mite-eradication-and-complete-collarette-cure-at-day-43

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major ...

 arcelormittal-revvity-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording losses in today’s pre-market tradin...

 lianbio-announces-presentation-of-data-from-phase-2a-study-of-infigratinib-in-patients-with-gastric-cancer-at-esmo-congress-2023

LianBio (NASDAQ:LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major ...

 raymond-james-maintains-outperform-on-lianbio-lowers-price-target-to-9

Raymond James analyst Dane Leone maintains LianBio (NASDAQ:LIAN) with a Outperform and lowers the price target from $15 to $9.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION